SHZ · 002437.SZ
Harbin Gloria Pharmaceuticals Co., Ltd
CN¥3.01+CN¥0.13 (+4.51%)
Harbin Gloria Pharmaceuticals Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.98% below the high.
Loading market information…
SHH · 688566.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:11 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Jiangsu Jibeier Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Jiangsu Jibeier Pharmaceutical Co., Ltd.’s forward annual dividend is CN¥0.52 per share, paid semi-annual. The forward yield is 1.93% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Jiangsu Jibeier Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jiangsu Jibeier Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jiangsu Jibeier Pharmaceutical Co., Ltd. is a pharmaceutical enterprise based in Zhenjiang, China, established in 2001. The company's core operations involve the research, development, manufacturing, and sales of a diverse range of pharmaceutical products, including chemical preparations, traditional Chinese medicine formulations, and active pharmaceutical ingredients (APIs). Its product portfolio addresses various health concerns, offering solutions for boosting white blood cell counts, enhancing the immune system, treating joint-related ailments, managing high blood pressure, combating ocular infections, alleviating bronchitis symptoms, and protecting liver function, among others. Additionally, Jiangsu Jibeier is actively engaged in developing new therapeutic drugs, with its pipeline focusing on treatments for conditions such as depression, oncology (tumors), and gastrointestinal disorders.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥239.43M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥3.01+CN¥0.13 (+4.51%)
Harbin Gloria Pharmaceuticals Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.98% below the high.
CN¥12.25+CN¥0.21 (+1.74%)
Zhejiang Garden Biopharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.74% below the high.
CN¥47.45-CN¥0.53 (-1.1%)
Hunan Warrant Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 27.22% below the high.
CN¥7.04+CN¥0.26 (+3.83%)
Jinghua Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.49% below the high.
CN¥13.76+CN¥0.55 (+4.16%)
Chongqing Pharscin Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.5% below the high.
CN¥4.82+CN¥0.13 (+2.77%)
Shanghai Kaibao Pharmaceutical CO.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.8% below the high.
CN¥4.74+CN¥0.07 (+1.5%)
Shanxi Zhendong Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 36.8% below the high.
CN¥19.87+CN¥0.07 (+0.35%)
Shenzhen Weiguang Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.02% below the high.
